Veracyte, Inc. disclosed lower-than-expected Decipher Prostate test volumes and reduced its full-year revenue guidance, leading to a significant stock decline. This has prompted legal investigations into the accuracy of the company's prior growth statements, indicating potential shareholder litigation.
Veracyte announced a significant miss on Decipher Prostate test volumes and subsequently lowered its 2026 revenue guidance. This news caused a substantial drop in the company's stock price, as it signals a slowdown in a key product's growth trajectory. Legal firms have initiated investigations, suggesting potential shareholder lawsuits over alleged misrepresentation of growth outlooks. This is a negative short-term catalyst for VCYT due to the immediate stock decline and the overhang of potential litigation. While the share repurchase authorization might offer some long-term support, the immediate concern for traders is the erosion of investor confidence and the financial implications of the guidance cut and legal scrutiny.